In a randomized trial, spironolactone was the winner. Spironolactone was the clear “winner” in this valuable study of resistant hypertension; the inverse relation with baseline PRA suggests that its efficacy is related, at least in part, to enhanced natriuresis.
The addition of spironolactone to patients with resistant hypertension currently treated with renin-angiotensin-aldosterone system (RAAS) blockers, calcium-channel blockers (CCBs), and a thiazidelike diuretic resulted in a significant reduction in systolic blood pressure, according to the results of a new study.
Combining two diuretics, amiloride and hydrochlorothiazide (HCTZ), results in a significant reduction in blood pressure, more so than when each drug is used alone, and has the beneficial effect of neutralizing undesirable changes in blood glucose and potassium, according to the results of a new study.
Men with erectile dysfunction had more than double the odds of having undiagnosed diabetes, whereas no association was seen for undiagnosed hypertension or undiagnosed hypercholesterolemia.